ArticleDiabetology & metabolic syndrome2026
Association of frailty and metabolism with multi-state model in fatty liver disease, diabetes mellitus and all-cause mortality.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveFrailty is a global public health issue, and metabolic syndrome (MetS) is also associated with a variety of adverse health outcomes. However, the relationship between the combined effects of these two factors and the occurrence and progression of long-term diseases remains unclear.
methodsThis is a population-based cohort study involving 165,555 participants from the UK Biobank. We combined frailty status scores with metabolic condition scores to assess the predictive value. Associations were assessed using multi-state model, corrected Cox models, restricted cubic spline, stratified analysis, Kaplan-Meier analysis.
resultsDuring the 12.7-year follow-up period, 3,585 individuals were newly diagnosed with metabolic-associated fatty liver disease (MAFLD), among whom 170 developed non-insulin-dependent diabetes mellitus (NIDDM) and 699 died from all causes. Compared with Group 1(neither frailty nor MetS), the HR and 95% confidence intervals for Group 4 (both frailty and MetS) was 2.92 (2.45-3.47) for MAFLD, 4.21 (2.23-7.96) for MAFLD→NIDDM, and 1.22 (0.75-2.02) for MAFLD→Death. The Kaplan-Meier analysis further confirmed these findings. Consistent findings regarding the frailty phenotype and MetS had also been observed in the progression of NIDDM.
conclusionThis study demonstrates a positive association between frailty phenotype and MetS in disease onset and progression, and their combined assessment enables a more effective early risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.